Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Allergy|January 23, 2016
Development and validation of the mastocytosis quality of life questionnaire: MC-QoLF Siebenhaar, E von Tschirnhaus, K Hartmann, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 27, 2005
Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responsesC M Trujillo-Vargas, K D Mayer, T Bickert, et al.
The Journal of Clinical Investigation|January 22, 2000
Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type IeT Imbach, B Schenk, E Schollen, et al.
Allergy|May 29, 2015
Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrateB L Zuraw, M Cicardi, H J Longhurst, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|October 25, 2008
Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestationsB Pérez-Dueñas, A García-Cazorla, M Pineda, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 5, 2017
H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE studyM Maurer, P Staubach, U Raap, et al.
British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2012
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticariaM Magerl, M Rother, T Bieber, et al.
Molecular Genetics and Metabolism|February 13, 2017
UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatmentJ Vockley, B Burton, G T Berry, et al.
Science (New York, N.Y.)|May 19, 1995
Dust measurements at high ecliptic latitudesM Baguhl, D P Hamilton, E Grün, et al.
Pageof 13